Big Pharma Dispersion

What's moving. Price feed failed this session (Alpaca 401), so no live levels — the read is catalyst-driven. The freshest development: Novo Nordisk has moved ahead of Lilly in the oral GLP-1 segment, with oral Wegovy holding a months-long head start over Lilly's newly approved pill Foundayo (orforglipron), per BioSpace and Foreign Policy Journal — a reversal of the injectable-era pecking order. Meanwhile the short leg is compressing: BioSpace reports pharma broadly gaining on dealmaking and policy tailwinds, and J&J already beat and raised its 2026 outlook.

Catalysts. FDA's Pharmacy Compounding Advisory Committee meets July 23–24 on seven peptides — two-way headline risk for both LLY and NVO (NBC notes FDA-scientist skepticism). Then Q2 prints from MRK, PFE, ABBV, AMGN, BMY. Confirmation signal: Foundayo launch scripts vs. oral Wegovy.

Variant perception. The standard long-obesity / short-patent-cliff book is now consensus and its short leg is being squeezed by sector-wide tailwinds; the desk sees more edge in the pair within the winners — NVO's oral lead against crowded LLY momentum — which the tape has not fully repriced.

Caveats. Evidence is thin on levels (snapshot failure), an X search on launch scripts returned nothing, and searches on MRK/PFE specifics were budget-cut. GSK's chronic-cough failure (Fierce Biotech) is a reminder single-name pipeline risk cuts both ways. Live markets in scope: LLY, NVO, MRK, PFE, ABBV, AMGN, BMY, JNJ.